Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Litemuppon Jul 10, 2018 9:28am

135 Views

Post# 28292071

RE:RE:Wait and watch

Yes halt and major news still on the way. The partner will not take on existing commitments . It will help with the next stage of development. The financing will close by mid week next week followed by announcement before fda meeting.

new2mjstocks wrote:
Litemupp your not answering question. you said "mark my words" HALT and BIG NEWS very soon . do you still beleive your comments and why would any partner be in the near future if they are doing a MAJOR dilution at .13?

Bullboard Posts

Debt-free cannabis company set for next stage of growth